Novavax (NVAX)
(Delayed Data from NSDQ)
$3.97 USD
+0.08 (2.06%)
Updated Apr 19, 2024 03:59 PM ET
After-Market: $3.97 0.00 (0.00%) 4:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Novavax, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 984 | 1,982 | 1,146 | 476 | 19 |
Cost Of Goods | 344 | 903 | 0 | 0 | 0 |
Gross Profit | 640 | 1,079 | 1,146 | 476 | 19 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,206 | 1,724 | 2,833 | 892 | 139 |
Income After Depreciation & Amortization | -567 | -645 | -1,687 | -417 | -121 |
Non-Operating Income | 38 | 11 | -7 | 14 | 2 |
Interest Expense | 14 | 20 | 21 | 15 | 14 |
Pretax Income | -543 | -654 | -1,715 | -418 | -133 |
Income Taxes | 2 | 4 | 29 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -545 | -658 | -1,744 | -418 | -133 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -545 | -658 | -1,744 | -418 | -133 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -525 | -616 | -1,674 | -410 | -113 |
Depreciation & Amortization (Cash Flow) | 41 | 29 | 13 | 6 | 7 |
Income After Depreciation & Amortization | -567 | -645 | -1,687 | -417 | -121 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 100.77 | 78.18 | 74.40 | 57.55 | 24.10 |
Diluted EPS Before Non-Recurring Items | -5.41 | -8.42 | -23.44 | -7.27 | -5.80 |
Diluted Net EPS (GAAP) | -5.41 | -8.42 | -23.44 | -7.27 | -5.51 |
Fiscal Year end for Novavax, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 291.34 | 186.99 | 424.43 | 80.95 |
Cost Of Goods | NA | 154.98 | 98.93 | 55.78 | 34.09 |
Gross Profit | NA | 136.37 | 88.06 | 368.65 | 46.87 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 319.94 | 213.69 | 313.20 | 359.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -183.57 | -125.63 | 55.45 | -312.76 |
Non-Operating Income | NA | 10.98 | -2.98 | 5.53 | 24.36 |
Interest Expense | NA | 4.12 | 2.86 | 3.12 | 4.32 |
Pretax Income | NA | -176.70 | -131.47 | 57.87 | -292.72 |
Income Taxes | NA | 1.69 | -0.70 | -0.14 | 1.18 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -178.39 | -130.78 | 58.01 | -293.91 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -178.39 | -130.78 | 58.01 | -293.91 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 123.68 | 103.43 | 104.07 | 86.16 |
Diluted EPS Before Non-Recurring Items | NA | -1.44 | -1.26 | 0.58 | -3.41 |
Diluted Net EPS (GAAP) | NA | -1.32 | -1.26 | 0.58 | -3.41 |